| 摘要: |
| 轻度认知障碍的实际发病率较高，对人们的日常生活影响较大，但是其发现较为困难，这对该疾病的早期诊断与治疗以及病程监测等方面提出了全新的挑战。轻度认知障碍生物标志物的发现将为该疾病的诊疗提供适时的帮助，最近，代谢组学技术在轻度认知障碍的生物标志物发现方面展示了许多新的研究结果。综述了近期代谢组学技术在轻度认知障碍研究中的重要发现，包括关键代谢物的鉴定、代谢途径的异常及其与轻度认知障碍病理生理过程的联系等。代谢组学技术的应用将为轻度认知障碍的早期诊断及个性化治疗等领域的发展提供新的思路和重要理论基础。 |
| 关键词: 轻度认知障碍 代谢组学 代谢物 生物标志物 |
| DOI：10.14188/j.ajsh.20240816001 |
| 分类号:R749.1 |
| 基金项目:国家自然科学基金（52073022）；武汉大学“基础-中南”共建项目培育基金（202205）；湖北省科技厅揭榜制科技项目（KJJB2023000058） |
|
| Progress on biomarkers of mild cognitive impairment from the perspective of metabolomics |
|
DAI Congshan1,2, CHONG Yufei1, XIA Wenguang1, LIU Wanhong2
|
|
1.The Affiliated Hospital of Hubei Provincial Government （Hubei Rehabilitation Hospital），Wuhan 430071， Hubei， China;2.Hubei Province Key Laboratory of Allergy and Immunology， Taikang Medical School （School of Basic Medical Sciences）， Wuhan University， Wuhan 430071， Hubei， China
|
| Abstract: |
| The actual incidence rate of mild cognitive impairment （MCI） is relatively high， and it has a significant impact on people’s well-being， but its discovery is relatively difficult， which poses a new challenge for early diagnosis treatment and the monitoring of the course of the disease. Biomarkers for MCI could provide timely assistance in its diagnosis and treatment. Recently， metabolomics technology has demonstrated promising results in identifying biomarkers for MCI. Therefore we review the key findings of metabolomics in MCI research， including the identification of crucial metabolites， abnormalities in metabolic pathways and their association with the pathophysiological processes of MCI. The application of metabolomics technology could provide new insights and important theoretical foundations for the development of the early diagnosis， precision medicine， and personalized treatment strategies of MCI. |
| Key words: mild cognitive impairment （MCI） metabolomics metabolite biomarker |
